香砂六君子汤加味治疗晚期非小细胞肺癌化疗致食欲减退的临床研究
|
摘要
目的
观察香砂六君子汤加味治疗晚期非小细胞肺癌化疗所致食欲减退的临床疗效及对患者血清白细胞介素-1(IL-1)水平变化的影响。
资料与方法
将60例符合纳入标准的晚期非小细胞肺癌患者随机分成两组,治疗组30例采用香砂六君子汤加味联合化疗,对照组30例采用醋酸甲地孕酮联合化疗,3周为一个化疗周期,2周期为一个疗程。观察食欲、血清IL-1水平、肿瘤客观疗效、体重、卡氏评分及不良反应的变化情况。
结果
1.每周期第21天两组的食欲评分均高于同一周期的第2天,差异有统计学意义(P<0.05)；每周期第21天治疗组食欲评分均略高于对照组,但差异无显著性(P>0.05)。
2.治疗第21、42天两组IL-1水平比治疗第2天水平均明显降低,差异有统计学意义(P<0.05);治疗第42天两组IL-1水平比治疗第21天水平有所降低,差异有统计学意义(P<0.05)；治疗第2、21、42天两组IL-1水平比较,差异均无统计学意义(P>0.05)。两组的IL-1水平与食欲评分进行等级相关分析显示,相关系数r均<0、P均<0.05,提示IL-1水平与食欲评分之间呈负相关关系。
3.在肿瘤客观疗效上,有效率：治疗组为43.3%、对照组为40.0%,稳定率：治疗组为83.3%、对照组为76.7%,两组比较,均无显著性差异(P>0.05)。
4.治疗后两组体重均有所增加,与治疗前比较,无显著性差异(P>0.05)；对照组体重略高于治疗组,两组比较,无显著性差异(P>0.05)。
5.治疗后两组卡氏评分均有提高,与治疗前比较,有显著性差异(P<0.05)；治疗组卡氏评分比对照组稍有提高,但无显著性差异(P>0.05)。
6.治疗组未出现水肿、高血压情况,两组均未见血栓性静脉炎发生；治疗组出现便秘情况低于对照组,两组比较,有显著性差异(P<0.05)。
7.治疗组出现白细胞降低、恶心呕吐及腹泻等化疗毒副反应的例数较对照组少,有显著性差异(P均<0.05)；两组在其余各项化疗毒性反应方面比较,无显著性差异(P均>0.05)。
结论
1.香砂六君子汤加味能明显改善晚期非小细胞肺癌患者化疗所致食欲减退、提高患者生活质量及降低IL-1的水平,疗效与醋酸甲地孕酮相当。
2.香砂六君子汤加味无醋酸甲地孕酮在水肿、高血压、便秘方面的副作用。
3.香砂六君子汤加味在减轻白细胞降低、恶心呕吐及腹泻等化疗毒副反应方面优于醋酸甲地孕酮。
Objective
To observe the clinical curative effect of the anorexia induced by chemotherapy in patients with advanced non-small cell lung cancer through Additive Xiangshaliujunzi Decoction and the influence on the change of serum level of interleukin-1(IL-1). Materials and Methods
The 60 non-small cell lung cancer patients according with standards were randomly divided into two groups,30 cases of the therapy group were treated with combined Additive Xiangshaliujunzi Decoction and chemotherapy,30 cases of the control group were treated with combined megestrol acetate and chemotherapy. A cycle of chemotherapy would be 3 weeks,while a course of treatment would include 2 cycles of chemotherapy.The observation indicators would contained patients'appetite,serum level of IL-1,tumor objective curative effect,body weight, karnofsky and side effects.The curative effects would be evaluated after one course of treatment.
Results
l.On the 21st day of a chemotherapy cycle, the scores of appetite ratings in both groups are higher than those of the 2nd day of the same chemotherapy cycle,and the difference is significant (P<0.05). On the 21st day of a chemotherapy cycle, the scores of appetite ratings in therapy group are slightly higher than those of the control group,but the difference is insignificant (P>0.05).
2.On the 21st and 42nd day of the treatment course, the serum level of IL-1 in two groups is lower than that of the 2nd day of the treatment course,and the difference is significant (P<0.05).On the 42nd day, the serum level of IL-1 in two groups is lower than that of the 21st day of the treatment course, and the difference is significant (P<0.05).On the 2nd, 21st and 42nd day,there is no significant difference(P>0.05) on the change of the serum level of IL-1 between two groups.The correlation coefficient between the serum level of IL-1 and appetite ratings is negative, and the difference is significant (P<0.05),which indicates that there exists a negative correlation between each other.
3.In objective curative effects of the tumor,therapy group attained the efficiency of 43.3% and the stability rate of 83.3%,while in control group the efficiency is 40.0% and the stability rate is 76.7%.The difference is insignificant (P>0.05) in aspects of the efficiency and the stability rate between two groups.
4.After the treatment, the patients in both groups gain weight than before the treatment, but the difference is insignificant(P>0.05).There is also no significant difference(P>0.05) in aspect of body weight between two groups after the treatment.
5.After the treatment, the scores of Kamofsky in both groups are higher than before the treatment, and the difference is significant (P<0.05).The scores of Kamofsky in therapy group are higher than the control group, but the difference is insignificant (P>0.05).
6.During the treatment,the therapy group has no case of edema, high blood pressure or thrombophlebitis.Patients with constipation in therapy group are fewer than the control group,and the difference is significant (P<0.05).
7.Patients with leukocyte reduction,nausea,vomiting or diarrhoea in therapy group are fewer than the control group,and the difference is significant (P<0.05).There is no significant difference (P>0.05) in other aspects of toxic and side effects between two groups. Conclusions
1.Additive Xiangshaliujunzi Decoction can obviously improve the anorexia induced by chemotherapy in patients with advanced non-small cell lung cancer, enhance the quality of life and reduce the serum level of IL-1.The curative effect is equivalent to that of megestrol acetate.
2.Additive Xiangshaliujunzi Decoction has no side effects on edema, high blood pressure or thrombophlebitis,while megestrol acetate has.
3.Additive Xiangshaliujunzi Decoction is better than megestrol acetate on relieving the toxic and side effects induced by chemotherapy,such as leukocyte reduction,nausea,vomiting or diarrhea.
观察香砂六君子汤加味治疗晚期非小细胞肺癌化疗所致食欲减退的临床疗效及对患者血清白细胞介素-1(IL-1)水平变化的影响。
资料与方法
将60例符合纳入标准的晚期非小细胞肺癌患者随机分成两组,治疗组30例采用香砂六君子汤加味联合化疗,对照组30例采用醋酸甲地孕酮联合化疗,3周为一个化疗周期,2周期为一个疗程。观察食欲、血清IL-1水平、肿瘤客观疗效、体重、卡氏评分及不良反应的变化情况。
结果
1.每周期第21天两组的食欲评分均高于同一周期的第2天,差异有统计学意义(P<0.05)；每周期第21天治疗组食欲评分均略高于对照组,但差异无显著性(P>0.05)。
2.治疗第21、42天两组IL-1水平比治疗第2天水平均明显降低,差异有统计学意义(P<0.05);治疗第42天两组IL-1水平比治疗第21天水平有所降低,差异有统计学意义(P<0.05)；治疗第2、21、42天两组IL-1水平比较,差异均无统计学意义(P>0.05)。两组的IL-1水平与食欲评分进行等级相关分析显示,相关系数r均<0、P均<0.05,提示IL-1水平与食欲评分之间呈负相关关系。
3.在肿瘤客观疗效上,有效率：治疗组为43.3%、对照组为40.0%,稳定率：治疗组为83.3%、对照组为76.7%,两组比较,均无显著性差异(P>0.05)。
4.治疗后两组体重均有所增加,与治疗前比较,无显著性差异(P>0.05)；对照组体重略高于治疗组,两组比较,无显著性差异(P>0.05)。
5.治疗后两组卡氏评分均有提高,与治疗前比较,有显著性差异(P<0.05)；治疗组卡氏评分比对照组稍有提高,但无显著性差异(P>0.05)。
6.治疗组未出现水肿、高血压情况,两组均未见血栓性静脉炎发生；治疗组出现便秘情况低于对照组,两组比较,有显著性差异(P<0.05)。
7.治疗组出现白细胞降低、恶心呕吐及腹泻等化疗毒副反应的例数较对照组少,有显著性差异(P均<0.05)；两组在其余各项化疗毒性反应方面比较,无显著性差异(P均>0.05)。
结论
1.香砂六君子汤加味能明显改善晚期非小细胞肺癌患者化疗所致食欲减退、提高患者生活质量及降低IL-1的水平,疗效与醋酸甲地孕酮相当。
2.香砂六君子汤加味无醋酸甲地孕酮在水肿、高血压、便秘方面的副作用。
3.香砂六君子汤加味在减轻白细胞降低、恶心呕吐及腹泻等化疗毒副反应方面优于醋酸甲地孕酮。
Objective
To observe the clinical curative effect of the anorexia induced by chemotherapy in patients with advanced non-small cell lung cancer through Additive Xiangshaliujunzi Decoction and the influence on the change of serum level of interleukin-1(IL-1). Materials and Methods
The 60 non-small cell lung cancer patients according with standards were randomly divided into two groups,30 cases of the therapy group were treated with combined Additive Xiangshaliujunzi Decoction and chemotherapy,30 cases of the control group were treated with combined megestrol acetate and chemotherapy. A cycle of chemotherapy would be 3 weeks,while a course of treatment would include 2 cycles of chemotherapy.The observation indicators would contained patients'appetite,serum level of IL-1,tumor objective curative effect,body weight, karnofsky and side effects.The curative effects would be evaluated after one course of treatment.
Results
l.On the 21st day of a chemotherapy cycle, the scores of appetite ratings in both groups are higher than those of the 2nd day of the same chemotherapy cycle,and the difference is significant (P<0.05). On the 21st day of a chemotherapy cycle, the scores of appetite ratings in therapy group are slightly higher than those of the control group,but the difference is insignificant (P>0.05).
2.On the 21st and 42nd day of the treatment course, the serum level of IL-1 in two groups is lower than that of the 2nd day of the treatment course,and the difference is significant (P<0.05).On the 42nd day, the serum level of IL-1 in two groups is lower than that of the 21st day of the treatment course, and the difference is significant (P<0.05).On the 2nd, 21st and 42nd day,there is no significant difference(P>0.05) on the change of the serum level of IL-1 between two groups.The correlation coefficient between the serum level of IL-1 and appetite ratings is negative, and the difference is significant (P<0.05),which indicates that there exists a negative correlation between each other.
3.In objective curative effects of the tumor,therapy group attained the efficiency of 43.3% and the stability rate of 83.3%,while in control group the efficiency is 40.0% and the stability rate is 76.7%.The difference is insignificant (P>0.05) in aspects of the efficiency and the stability rate between two groups.
4.After the treatment, the patients in both groups gain weight than before the treatment, but the difference is insignificant(P>0.05).There is also no significant difference(P>0.05) in aspect of body weight between two groups after the treatment.
5.After the treatment, the scores of Kamofsky in both groups are higher than before the treatment, and the difference is significant (P<0.05).The scores of Kamofsky in therapy group are higher than the control group, but the difference is insignificant (P>0.05).
6.During the treatment,the therapy group has no case of edema, high blood pressure or thrombophlebitis.Patients with constipation in therapy group are fewer than the control group,and the difference is significant (P<0.05).
7.Patients with leukocyte reduction,nausea,vomiting or diarrhoea in therapy group are fewer than the control group,and the difference is significant (P<0.05).There is no significant difference (P>0.05) in other aspects of toxic and side effects between two groups. Conclusions
1.Additive Xiangshaliujunzi Decoction can obviously improve the anorexia induced by chemotherapy in patients with advanced non-small cell lung cancer, enhance the quality of life and reduce the serum level of IL-1.The curative effect is equivalent to that of megestrol acetate.
2.Additive Xiangshaliujunzi Decoction has no side effects on edema, high blood pressure or thrombophlebitis,while megestrol acetate has.
3.Additive Xiangshaliujunzi Decoction is better than megestrol acetate on relieving the toxic and side effects induced by chemotherapy,such as leukocyte reduction,nausea,vomiting or diarrhea.
引文
[1]叶任高,等.内科学—6版.北京：人民卫生出版社,2004.1：116.
[2]汤钊猷.现代肿瘤学.上海医科大学出版社,1993：637.
[3]孙燕.内科肿瘤学[M].北京：人民卫生出版社,2001：994-997.
[4]于世英.临床肿瘤学.北京：科学出版社,2006：499-500.
[5]Alessandro Laviano, Michael M Meguid, Filippo Rossi-Fanelli, et al. Cancer anorexia:clinical implications, Pathogenesis, and therapeutic strategies. The Lancet Oncology,2003,4:686-694.
[6]Mantovani G, Maccio A, Lai P, et al. Cytokine involvement in cancer anorexia/cachexia, role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and impr-ovement of clinical symptoms. Crit Rev Oncol 1998,9:99-106.
[7]陆益,吴洪斌.甲地孕酮的不良反应[J].药物不良反应杂志,2003,1(1)：26-27.
[8]邓铁涛主编.中医诊断学.第五版.上海：上海科学技术出版社,1985：54-55.
[9]孙秉严.治癌秘方——我治癌34年医案.北京：华龄出版社,1992：289,305,308.
[10]邓铁涛.实用中医诊断学.北京：人民卫生出版社,2004.10：515-516.
[11]朱文锋.中医诊断学(新世纪全国高等中医药院校规划教材).北京：中国中医药出版社,2002.8：186,196-197.
[12]孙燕,哈献文主编.临床肿瘤诊疗关键.南宁：广西科学技术出版社,1999.633-643
[13]刘嘉湘.辨证治疗原发性肺癌310例疗效分析.上海中医药杂志,1985,12：3.
[14]周仲瑛.中医内科学.北京：中国中医药出版社,2003.1：468.
[15]何依群.八珍冲剂治疗化疗后食欲减退的临床观察[J].海南医学,2007,18(11)：87.
[16]陈惠东,苏坤.参苓白术散加减治疗恶性肿瘤化疗后消化不良36例临床观察[J].山西中医,2007,23(5)：22.
[17]俞勇,等.半夏泻心汤加味治疗胃癌术后化疗消化道反应疗效观察[J].浙江中医药大学学报,2006,30(4)：401-402.
[18]郭晓红,谢炜,陈宝田.开胃方预防恶性肿瘤化疗性胃肠功能障碍的临床观察[J].广东药学院学报,2006,22(3)：333-335.
[19]陈敏.健脾和胃汤治疗化疗后食欲减退30例观察[J].实用中医药杂志,2001,17(2)：7.
[20]于世英.临床肿瘤学.北京：科学出版社,2006：499-500.
[21]陈振东,孙燕,王肇炎.实用肿瘤并发症诊断治疗学[M].合肥：安徽科学技术出版社,1997：69.
[22]Heisler LK, Cowley MA, Tecott LH, et al. Activation of central melanocortin pathways by fenfluramine. Science 2002,297:609-611.
[23]Shintani F, Kanba S, Nakaki T, et al. Interleukin-1 beta augments release of norepinephrine, dopamine and serotonin in the rat anterior hypothalamus. J Neurosci 1993,13:3574-81.
[24]Opara EI, Laviano A, Meguid MM, Yang Z-J. Correlation between food intake and CSF IL-1 in anorectic tumor bearing rats. Neuro Report,1995,6:750-752.
[25]Laviano A, Gleason JR, Meguid MM, et al. Effects of intra-VMN mianserin and IL-1ra on meal number in anorectic tumor-bearing rats. J Investig Med,2000,48:40-48.
[26]Inui A. Cancer anorexia-cachexia syndrome:current issues in research and management. CA Cancer J Clin,2002,52:72-91.
[27]Maltoni M, Nanni O, Scarpi E, et al. High-dose progestins for the treatment of cancer anorexia-cachexia:a systematic review of randomised clinical trials. Ann Oncol,2001,12:289-300.
[28]汪悦,曾莉.实用名方大全.南京：江苏科学技术出版社,2005.11：558-561.
[29]李笑然.中药学.苏州：苏州大学出版社,2004.8：266.
[30]何裕民.现代中医肿瘤学.北京：中国协和医科大学出版社,2005.9：530.
[31]傅智敏,朱曙东,金华.香砂六君子汤对大鼠急性胃粘膜损伤的保护作用[J].浙江中医学院学报,2000,24(4)：52.
[32]李建荣.香砂六君冲剂的药效学研究,中成药研究荟萃全国首届中成药学术研讨会论文集,1992,10.
[33]谢海青,尹昌金,熊磊.香砂六君子汤抗大鼠胃粘膜损伤并脾气虚证实验研究[J].云南中医学院学报,1992,15(3)：15-17.
[34]侯家玉,赵凤志,洪缨,等.三种方剂水煎液对大鼠实验性返流性胃炎保护作用的研究[J].中国中药杂志,1992,17(11)：682-684.
[35]张英福,郑天珍,李伟,等.香砂六君子汤及其成分对大鼠离体胃平滑肌条运动的影响[J].兰州医学院学报,1999,25(2)：1-4.
[36]邵庭荫,等.香砂六君子丸对胃肠道的影响及毒性.中药药理与临床,1990,6(2)：5.
[37]黄河,谢海青,李梅丽.香砂六君子汤抗大鼠胃粘膜损伤的免疫组化研究[J].国医论坛,1995,(49)：42-43.
[38]黄梅,张仲海,夏天.四君子汤对脾虚患者血清可溶性细胞粘附分子-1水平和单核细胞功能的影响[J].中国中西医结合杂志,1999,19(5)：27.
[39]许得盛,沈自尹,王文健,等.右归饮、四君子汤、桃红四物汤调节肾虚、脾虚、血瘀证患者免疫功能的观察[J].中国中西医结合杂志,1999,19(12)：712-714.
[40]季宇彬.中药复方化学与药理.北京：人民卫生出版社,2003：340-341.
[41]侯家玉.三种方剂水煎液对大鼠实验性返流性胃炎保护作用的研究.中国中药杂志,1992,11(11)：682.
[1]杨金坤,郑坚.邱佳信治疗消化道恶性肿瘤的学术经验[J].上海中医药杂志,1995,29(2)：10.
[2]王海明,杨明会.六君子汤治疗消化道肿瘤化疗副反应临床观察[J].中国中医急症,2008,17(4)：459.
[3]刘海晔,周洁.注射用黄芪多糖联合化疗减毒增效96例临床观察[J].天津药学,2007,19(2)：31-32.
[4]何依群,姜鹤群,王少龙,等.八珍冲剂治疗化疗后食欲减退的临床观察[J].海南医学,2007,18(11)：87.
[5]付文胜.六君子汤防治恶性肿瘤化疗后便秘临床观察[J].河北中医,2005,27(2)：117.
[6]徐阳,于淑珍,邵丽华.参芪扶正注射液联合八珍汤减轻化疗副反应临床观察[J].中国中医急症,2008,17(3)：321.
[7]黄学武,黄健洲.四君子汤加减对恶性肿瘤化疗毒副作用的影响[J].吉林中医药,2004,24(12)：27.
[8]付文胜.参术汤治疗恶性肿瘤化疗后白细胞减少临床观察[J].现代中西医结合杂志,2005,14(10)：1297.
[9]白献红,洪锡田.参麦防治肿瘤化疗所致骨髓抑制[J].医药论坛杂志,2003,24(15)：59.
[10]傅文红,陈丽贤,黄守松,等.人参多糖注射液在卵巢癌患者化疗中的作用[J].药学服务与研究,2005,5(2)：169.
[11]郭洪斌,李惠娟,王娟,等.黄芪注射液在化疗中的作用及对免疫功能的影响[J].中国中医药科技,2005,12(5)：309.
[12]孙一予,马少军,贾英杰,等.参芪扶正注射液联合化疗对非小细胞肺癌患者外周血细胞水平及免疫细胞活性的影响[J].中国中医急症,2007,16(7)：776.
[13]李艳秋,冯艳,王育强,等.生脉注射液对中晚期肺癌化疗患者免疫功能调节作用研究[J].中华中医药学刊,2007,25(2)：268.
[14]郝文.参麦注射液对阿霉素心脏毒性反应的防治作用[J].中医药临床杂志,2007,19(1)：5.
[15]柏长青,遆新宇,刘关键,等.党参、黄芪提取物注射液对减轻肺癌患者化疗毒副反应和生存质量影响的研究[J].中国康复医学杂志,2006,21(8)：707.
[16]陆素琴.黄芪注射液对顺铂所致肾毒性的防护观察[J].湖北中医杂志,2004,26(8)：12.
[2]汤钊猷.现代肿瘤学.上海医科大学出版社,1993：637.
[3]孙燕.内科肿瘤学[M].北京：人民卫生出版社,2001：994-997.
[4]于世英.临床肿瘤学.北京：科学出版社,2006：499-500.
[5]Alessandro Laviano, Michael M Meguid, Filippo Rossi-Fanelli, et al. Cancer anorexia:clinical implications, Pathogenesis, and therapeutic strategies. The Lancet Oncology,2003,4:686-694.
[6]Mantovani G, Maccio A, Lai P, et al. Cytokine involvement in cancer anorexia/cachexia, role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and impr-ovement of clinical symptoms. Crit Rev Oncol 1998,9:99-106.
[7]陆益,吴洪斌.甲地孕酮的不良反应[J].药物不良反应杂志,2003,1(1)：26-27.
[8]邓铁涛主编.中医诊断学.第五版.上海：上海科学技术出版社,1985：54-55.
[9]孙秉严.治癌秘方——我治癌34年医案.北京：华龄出版社,1992：289,305,308.
[10]邓铁涛.实用中医诊断学.北京：人民卫生出版社,2004.10：515-516.
[11]朱文锋.中医诊断学(新世纪全国高等中医药院校规划教材).北京：中国中医药出版社,2002.8：186,196-197.
[12]孙燕,哈献文主编.临床肿瘤诊疗关键.南宁：广西科学技术出版社,1999.633-643
[13]刘嘉湘.辨证治疗原发性肺癌310例疗效分析.上海中医药杂志,1985,12：3.
[14]周仲瑛.中医内科学.北京：中国中医药出版社,2003.1：468.
[15]何依群.八珍冲剂治疗化疗后食欲减退的临床观察[J].海南医学,2007,18(11)：87.
[16]陈惠东,苏坤.参苓白术散加减治疗恶性肿瘤化疗后消化不良36例临床观察[J].山西中医,2007,23(5)：22.
[17]俞勇,等.半夏泻心汤加味治疗胃癌术后化疗消化道反应疗效观察[J].浙江中医药大学学报,2006,30(4)：401-402.
[18]郭晓红,谢炜,陈宝田.开胃方预防恶性肿瘤化疗性胃肠功能障碍的临床观察[J].广东药学院学报,2006,22(3)：333-335.
[19]陈敏.健脾和胃汤治疗化疗后食欲减退30例观察[J].实用中医药杂志,2001,17(2)：7.
[20]于世英.临床肿瘤学.北京：科学出版社,2006：499-500.
[21]陈振东,孙燕,王肇炎.实用肿瘤并发症诊断治疗学[M].合肥：安徽科学技术出版社,1997：69.
[22]Heisler LK, Cowley MA, Tecott LH, et al. Activation of central melanocortin pathways by fenfluramine. Science 2002,297:609-611.
[23]Shintani F, Kanba S, Nakaki T, et al. Interleukin-1 beta augments release of norepinephrine, dopamine and serotonin in the rat anterior hypothalamus. J Neurosci 1993,13:3574-81.
[24]Opara EI, Laviano A, Meguid MM, Yang Z-J. Correlation between food intake and CSF IL-1 in anorectic tumor bearing rats. Neuro Report,1995,6:750-752.
[25]Laviano A, Gleason JR, Meguid MM, et al. Effects of intra-VMN mianserin and IL-1ra on meal number in anorectic tumor-bearing rats. J Investig Med,2000,48:40-48.
[26]Inui A. Cancer anorexia-cachexia syndrome:current issues in research and management. CA Cancer J Clin,2002,52:72-91.
[27]Maltoni M, Nanni O, Scarpi E, et al. High-dose progestins for the treatment of cancer anorexia-cachexia:a systematic review of randomised clinical trials. Ann Oncol,2001,12:289-300.
[28]汪悦,曾莉.实用名方大全.南京：江苏科学技术出版社,2005.11：558-561.
[29]李笑然.中药学.苏州：苏州大学出版社,2004.8：266.
[30]何裕民.现代中医肿瘤学.北京：中国协和医科大学出版社,2005.9：530.
[31]傅智敏,朱曙东,金华.香砂六君子汤对大鼠急性胃粘膜损伤的保护作用[J].浙江中医学院学报,2000,24(4)：52.
[32]李建荣.香砂六君冲剂的药效学研究,中成药研究荟萃全国首届中成药学术研讨会论文集,1992,10.
[33]谢海青,尹昌金,熊磊.香砂六君子汤抗大鼠胃粘膜损伤并脾气虚证实验研究[J].云南中医学院学报,1992,15(3)：15-17.
[34]侯家玉,赵凤志,洪缨,等.三种方剂水煎液对大鼠实验性返流性胃炎保护作用的研究[J].中国中药杂志,1992,17(11)：682-684.
[35]张英福,郑天珍,李伟,等.香砂六君子汤及其成分对大鼠离体胃平滑肌条运动的影响[J].兰州医学院学报,1999,25(2)：1-4.
[36]邵庭荫,等.香砂六君子丸对胃肠道的影响及毒性.中药药理与临床,1990,6(2)：5.
[37]黄河,谢海青,李梅丽.香砂六君子汤抗大鼠胃粘膜损伤的免疫组化研究[J].国医论坛,1995,(49)：42-43.
[38]黄梅,张仲海,夏天.四君子汤对脾虚患者血清可溶性细胞粘附分子-1水平和单核细胞功能的影响[J].中国中西医结合杂志,1999,19(5)：27.
[39]许得盛,沈自尹,王文健,等.右归饮、四君子汤、桃红四物汤调节肾虚、脾虚、血瘀证患者免疫功能的观察[J].中国中西医结合杂志,1999,19(12)：712-714.
[40]季宇彬.中药复方化学与药理.北京：人民卫生出版社,2003：340-341.
[41]侯家玉.三种方剂水煎液对大鼠实验性返流性胃炎保护作用的研究.中国中药杂志,1992,11(11)：682.
[1]杨金坤,郑坚.邱佳信治疗消化道恶性肿瘤的学术经验[J].上海中医药杂志,1995,29(2)：10.
[2]王海明,杨明会.六君子汤治疗消化道肿瘤化疗副反应临床观察[J].中国中医急症,2008,17(4)：459.
[3]刘海晔,周洁.注射用黄芪多糖联合化疗减毒增效96例临床观察[J].天津药学,2007,19(2)：31-32.
[4]何依群,姜鹤群,王少龙,等.八珍冲剂治疗化疗后食欲减退的临床观察[J].海南医学,2007,18(11)：87.
[5]付文胜.六君子汤防治恶性肿瘤化疗后便秘临床观察[J].河北中医,2005,27(2)：117.
[6]徐阳,于淑珍,邵丽华.参芪扶正注射液联合八珍汤减轻化疗副反应临床观察[J].中国中医急症,2008,17(3)：321.
[7]黄学武,黄健洲.四君子汤加减对恶性肿瘤化疗毒副作用的影响[J].吉林中医药,2004,24(12)：27.
[8]付文胜.参术汤治疗恶性肿瘤化疗后白细胞减少临床观察[J].现代中西医结合杂志,2005,14(10)：1297.
[9]白献红,洪锡田.参麦防治肿瘤化疗所致骨髓抑制[J].医药论坛杂志,2003,24(15)：59.
[10]傅文红,陈丽贤,黄守松,等.人参多糖注射液在卵巢癌患者化疗中的作用[J].药学服务与研究,2005,5(2)：169.
[11]郭洪斌,李惠娟,王娟,等.黄芪注射液在化疗中的作用及对免疫功能的影响[J].中国中医药科技,2005,12(5)：309.
[12]孙一予,马少军,贾英杰,等.参芪扶正注射液联合化疗对非小细胞肺癌患者外周血细胞水平及免疫细胞活性的影响[J].中国中医急症,2007,16(7)：776.
[13]李艳秋,冯艳,王育强,等.生脉注射液对中晚期肺癌化疗患者免疫功能调节作用研究[J].中华中医药学刊,2007,25(2)：268.
[14]郝文.参麦注射液对阿霉素心脏毒性反应的防治作用[J].中医药临床杂志,2007,19(1)：5.
[15]柏长青,遆新宇,刘关键,等.党参、黄芪提取物注射液对减轻肺癌患者化疗毒副反应和生存质量影响的研究[J].中国康复医学杂志,2006,21(8)：707.
[16]陆素琴.黄芪注射液对顺铂所致肾毒性的防护观察[J].湖北中医杂志,2004,26(8)：12.